Henry Schein Company Profile (NASDAQ:HSIC)

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein, Inc. (NASDAQ:HSIC) released its earnings results on Tuesday, May, 9th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.65 by $0.11. The business earned $2.92 billion during the quarter, compared to analysts' expectations of $2.83 billion. Henry Schein had a net margin of 4.53% and a return on equity of 19.74%. The firm's revenue was up 7.7% on a year-over-year basis. During the same period last year, the business earned $1.41 earnings per share. View Henry Schein's Earnings History.

Henry Schein updated its FY17 earnings guidance on Tuesday, May, 9th. The company provided earnings per share guidance of $7.17-7.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.25.

15 brokers have issued 1 year price objectives for Henry Schein's stock. Their forecasts range from $160.00 to $208.00. On average, they expect Henry Schein's share price to reach $181.46 in the next twelve months. View Analyst Ratings for Henry Schein.

Here are some recent quotes from research analysts about Henry Schein stock:

• 1. According to Zacks Investment Research, "In the past three months, Henry Schein has consistently outperformed the S&P 500 Market at large with respect to share price movement. Apart from balanced segmental growth across all its operating segments, the company’s share gains in both the U.S. and overseas markets raise optimism. Management is also upbeat about several strategic tie ups made during the reported quarter. We are also positive about Henry Schein’s buyout of Marrodent and SAS which have the potential to capture the bountiful dental market opportunities. On the flip side despite a strong quarterly show last time, the company’s unchanged EPS guidance for 2017 is uninspiring. Meanwhile, Henry Schein’s venture in digital dentistry through Dentsply Sirona deal may intensify its already weak operating margin scenario on escalating education and training expenses. Also, foreign currency fluctuations continued to mar the company’s financials." (6/23/2017)
• 2. Evercore ISI analysts commented, "HSIC continues to deliver consistent HSD to LDD EPS growth despite an operating environment that has been somewhat mixed, albeit North American Dental continues to show signs of recovery. With the acquisition engine still churning and an elevated level of buybacks, management has been able to deliver the type of TSR expected and thus the valuation remains notably elevated on an absolute basis (less so on a relative basis). While we also value consistency and predictability, we acknowledge we missed the November entry point (fears of US slowdown) and thus at current levels see risk / reward as more fully balanced (particularly with extra week headwind in 2017 + unfavorable Fx environment). Given this dynamic we reiterate our Hold rating and argue shares are now accurately pricing in the current operating environment. Thus we await another period of uncertainty prior to revisiting our long-term constructive view on shares." (2/21/2017)

Some companies that are related to Henry Schein include Alexion Pharmaceuticals (ALXN), Incyte Corporation (INCY), Zimmer Biomet Holdings (ZBH), Astellas Pharma (ALPMY), Illumina (ILMN), Edwards Lifesciences Corporation (EW), Cardinal Health (CAH), C.R. Bard (BCR), Cerner Corporation (CERN), Mylan N.V. (MYL), AmerisourceBergen Corporation (Holding Co) (ABC), Quintiles Transitional Holdings (Q), Lonza Group Ag (LZAGY), Laboratory Corporation of America Holdings (LH), Eisai Co., Ltd (ESALY), Smith & Nephew SNATS (SNN), BioMarin Pharmaceutical (BMRN) and Quest Diagnostics Incorporated (DGX).

Henry Schein's management team includes the folowing people:

• Stanley M. Bergman, Chairman of the Board, Chief Executive Officer
• James P. Breslawski CPA, President, Director; Chief Executive Officer of Henry Schein Global Dental Group
• Steven Paladino CPA, Chief Financial Officer, Executive Vice President, Director
• Peter McCarthy, President of Global Animal Health Group
• David C. McKinley, President of Corporate Commercial Development Group, Chief Commercial Officer
• Bob Minowitz, President, International Dental Group, EMEA Region
• Bridget A. Ross, President of Global Medical Group
• Gerald A. Benjamin, Chief Administrative Officer, Executive Vice President, Director
• Mark E. Mlotek, Chief Strategic Officer, Executive Vice President, Director
• Karen N. Prange, Executive Vice President; Chief Executive Officer of Global Animal Health, Medical and Dental Surgical Group

Henry Schein's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Alecta Pensionsforsakring Omsesidigt (3.16%), Swedbank (1.61%), Fisher Asset Management LLC (0.53%), Chevy Chase Trust Holdings Inc. (0.34%), Tesco Pension Investment Ltd (0.30%) and Bank of Montreal Can (0.21%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lonnie Shoff, Lorelei Mcglynn, Louis W Sullivan, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Norman S Matthews, Paul Brons, Paul Rose, Peter M Mccarthy, Philip A Laskawy, Robert Minowitz, Stanley Komaroff, Stanley M Bergman and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

Henry Schein's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Vontobel Asset Management Inc., Fisher Asset Management LLC, State of Alaska Department of Revenue, Neville Rodie & Shaw Inc., Fox Run Management L.L.C., Chevy Chase Trust Holdings Inc. and Exxonmobil Investment Management Inc. TX. Company insiders that have sold Henry Schein stock in the last year include Donald J Kabat, Gerald A Benjamin, James A Harding, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Insider Buying and Selling for Henry Schein.

Henry Schein's stock was acquired by a variety of institutional investors in the last quarter, including AMI Asset Management Corp, Swedbank, Mn Services Vermogensbeheer B.V., Bank of Montreal Can, Baldwin Brothers Inc. MA, National Pension Service, Anderson Hoagland & Co. and Oakbrook Investments LLC. View Insider Buying and Selling for Henry Schein.

Shares of Henry Schein can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Henry Schein stock can currently be purchased for approximately $184.92.